PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25688159-10	2015	CONCLUSIONS: Targeting HER2(+) and HER2(-) tumors with aATC infusions induced antitumor responses, increases in Th1 cytokines, and IL12 serum levels that suggest that aATC infusions vaccinated patients against their own tumors.	aatc	55-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27	
25688159-10	2015	CONCLUSIONS: Targeting HER2(+) and HER2(-) tumors with aATC infusions induced antitumor responses, increases in Th1 cytokines, and IL12 serum levels that suggest that aATC infusions vaccinated patients against their own tumors.	aatc	55-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39	
25688159-10	2015	CONCLUSIONS: Targeting HER2(+) and HER2(-) tumors with aATC infusions induced antitumor responses, increases in Th1 cytokines, and IL12 serum levels that suggest that aATC infusions vaccinated patients against their own tumors.	aatc	167-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27	
25688159-10	2015	CONCLUSIONS: Targeting HER2(+) and HER2(-) tumors with aATC infusions induced antitumor responses, increases in Th1 cytokines, and IL12 serum levels that suggest that aATC infusions vaccinated patients against their own tumors.	aatc	167-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39